Article
Microbiology
Abbas Karimi, Elham Mohebbi, Sandrine Mckay-Chopin, Hamideh Rashidian, Maryam Hadji, Vahideh Peyghambari, Maryam Marzban, Ahmad Naghibzadeh-Tahami, Mahin Gholipour, Farin Kamangar, Massimo Tommasino, Tarik Gheit, Kazem Zendehdel
Summary: This study analyzed the detection of alpha-, beta-, and gamma-HPVs in oral rinse samples of HNSCC cases and controls in Iran, finding that the contribution of alpha-HPVs to HNSCC in Iran is lower than global prevalence, and high-risk alpha-HPVs or cutaneous beta- and gamma-HPVs were not associated with HNSCC development.
MICROBIOLOGY SPECTRUM
(2022)
Review
Biochemistry & Molecular Biology
Xin Zhou, Xiaoshen Wang
Summary: This review provides a detailed illustration of the biology, genomic features, and immune landscapes of HPV-associated HNSCC, supporting the synergistic effect of radioimmunotherapy. Current evidence and ongoing clinical trials suggest the potential of radioimmunotherapy in recurrent/metastatic or definitive settings. Future challenges include optimization of radiotherapy and the incorporation of novel therapeutic options.
Article
Oncology
Xinyi Liu, Ping Liu, Rebecca D. Chernock, Krystle A. Lang Kuhs, James S. Lewis, Hua Li, Hiram A. Gay, Wade L. Thorstad, Xiaowei Wang
Summary: This study identified differences in tumor microenvironment (TME) associated with HPV infection in OPSCC, with enrichment of specific cell types in HPV+ and HPV- OPSCCs. By constructing a coexpression network, it was found that HPV+ OPSCCs exhibit elevated immune activities and suppressed extracellular matrix-related activities compared to HPV- OPSCCs. Clinical analysis showed that TME-relevant genes were closely linked to prognosis and therapy response in OPSCC, with results validated in an independent OPSCC cohort.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Masato Mima, Atsushi Okabe, Takayuki Hoshii, Takuya Nakagawa, Tomoya Kurokawa, Satoru Kondo, Harue Mizokami, Masaki Fukuyo, Ryoji Fujiki, Bahityar Rahmutulla, Tomokazu Yoshizaki, Toyoyuki Hanazawa, Kiyoshi Misawa, Atsushi Kaneda
Summary: Human papillomavirus (HPV) plays a causal role in the development of head and neck squamous cell carcinoma (HNSCC) by integrating into the host genome and causing genomic alterations. This study analyzed the epigenome, transcriptome, and interactome of HPV-positive HNSCCs to understand the role of epigenetic dysregulation in tumorigenesis. The results showed that genes neighboring HPV integration sites were upregulated and correlated with oncogenic phenotypes in HPV-positive HNSCCs. The epigenetic activation of HPV-interacting regions (HPVIRs) contributed to the genesis of HPV-positive HNSCC.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Editorial Material
Genetics & Heredity
David J. Peace, Evgeny Izumchenko, David Sidransky
Summary: A study uses single-cell RNA sequencing to analyze human papillomavirus (HPV)-positive and -negative oropharyngeal squamous cell carcinoma, discovering significant diversity within and between tumors. In HPV-positive tumors, subsets of malignant cells are identified with undetectable HPV expression and decreased HPV-related phenotypes, potentially impacting prognosis and therapeutic response.
Review
Immunology
Huanhuan Wang, Qin Zhao, Yuyu Zhang, Qihe Zhang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, Lingbin Meng, Ying Xin, Xin Jiang
Summary: Head and neck cancer, primarily head and neck squamous cell carcinoma, is commonly treated with surgery, radiotherapy, chemotherapy, and immunotherapy. Immunotherapy, particularly for HPV-positive patients, has shown promising results possibly due to higher immune cell infiltration and differential expression of immune checkpoints in tumors. Personalized immunotherapy trials are also being conducted in HPV-positive patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Mark D. Wilkie, Emad A. Anaam, Andrew S. Lau, Carlos P. Rubbi, Nikolina Vlatkovic, Terence M. Jones, Mark T. Boyd
Summary: This study investigated the metabolic profile and potential role of anti-metabolic therapeutics in radiosensitization of HPV-positive SCCHN. Results showed that these cells have a diverse metabolic phenotype and require a complex anti-metabolic approach to sensitize them to radiation. This finding may offer a platform for treatment de-intensification in clinical settings by reducing radiation doses.
Article
Oncology
Kayla R. Getz, Emily Bellile, Katie R. Zarins, Cailey Rullman, Steven B. Chinn, Jeremy M. G. Taylor, Laura S. Rozek, Gregory T. Wolf, Alison M. Mondul
Summary: The study identified a significant inverse association between statin use and overall death, disease-specific death, and recurrence in untreated HNSCC patients. This protective effect was particularly pronounced in patients with HPV-positive disease.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Biology
Delphine Avril, Jean-Philippe Foy, Jebrane Bouaoud, Vincent Gregoire, Pierre Saintigny
Summary: This article aims to review recently proposed biomarkers of radioresistance in HPV-negative HNSCC, which can be useful for stratifying tumor patients based on their predicted level of radioresistance.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Immunology
Yourong Jiang, Siwei Zhang, Lu Tang, Rui Li, Jinglei Zhai, Suisui Luo, Yiman Peng, Xiaohang Chen, Lanlan Wei
Summary: This study constructed a single-cell atlas of macrophages from HPV-negative and HPV-positive HNSCC patients using single-cell RNA sequencing data. The results showed that macrophages in HPV-positive HNSCC exhibit stronger phagocytic ability, while TCR+ macrophages play a critical role in the HNSCC microenvironment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Ping Zhou, Yi-Feng Yu, Chen-Lu Lian, Jun Wang, Ren-Gong Zhuo, San-Gang Wu
Summary: HPV-positive HNSCC patients have better survival outcomes and HPV-negative status, N3 stage, bone metastases, and lung metastases are associated with worse outcomes. Determination of HPV status may guide clinicians in treatment decisions for stage IV HNSCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Medicine, General & Internal
Mayur D. Mody, James W. Rocco, Sue S. Yom, Robert Haddad, Nabil F. Saba
Summary: Head and neck cancer is the seventh most common type of cancer worldwide, with the predominant risk factors being tobacco use, alcohol abuse, and oncogenic viruses. Treatment typically involves a multidisciplinary approach with surgery, radiotherapy, and systemic therapy, and is challenging due to site-specific and histology-specific variations.
Review
Biochemistry & Molecular Biology
Sindhu Nair, James A. Bonner, Markus Bredel
Summary: EGFR is overexpressed in head and neck squamous cell carcinoma and anti-EGFR strategies have shown some clinical benefit but often lead to resistance. Mutations in various domains of the EGFR gene can impact drug binding, radiation response, and overall survival in HNSCC patients. Understanding the EGFR mutational landscape and its effects on treatment resistance can help stratify patients for targeted therapies and maximize therapeutic benefits.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Yihong Hu, Yucheng Han, Minhui He, Yanqun Zhang, Xianqiong Zou
Summary: Head and neck squamous cell carcinoma (HNSCC) is the most common tumor affecting the head and neck, characterized by rapid onset, lack of early diagnosis, drug resistance, relapse, and systemic adverse effects. S100 proteins have been associated with HNSCC, including S100A8, S100A9, and S100A14, which inhibit tumor cell proliferation. S100A4 enhances cancer stem cell properties and promotes tumor cell migration. Several signaling pathways, such as Hippo, nuclear factor κB, and phosphatidylinositol kinase/protein kinase B/mammalian target of rapamycin, involve S100 proteins in the initiation and progression of HNSCC. Long non-coding RNAs and microRNAs also play a role in regulating the expression of S100 proteins in HNSCC. Reducing the expression of certain S100 proteins may improve the chemosensitivity of HNSCC. Therefore, S100 proteins could serve as markers and targets for the prevention, diagnosis, and treatment of HNSCC.
Article
Otorhinolaryngology
Alyssa Larish, Linda Yin, Gretchen Glaser, Eric Moore, Jamie Bakkum-Gamez, David Routman, Daniel Ma, Daniel Price, Jeffrey Janus, Katharine Price, Ashish Chintakuntlawar, Michelle Neben-Wittich, Robert Foote, Kathryn Van Abel
Summary: The study found that 37.0% of women with HPV-positive oropharyngeal squamous cell carcinoma had a history of HPV-related anogenital disease, with the cervix being the most common site. Among those with a history, 94.1% required procedures to diagnose or treat HPV lesions.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
(2021)